Eric Karas Acquires Shares in ARS Pharmaceuticals
Chief Commercial Officer Eric Karas purchased 25,000 shares of ARS Pharmaceuticals.
Key Points
- Eric Karas, the Chief Commercial Officer of ARS Pharmaceuticals, bought 25,000 shares at $1.5 each on June 12, 2026.
- ARS Pharmaceuticals, trading on NasdaqGM under the ticker SPRY, has a market cap of about $969.2 million and a 52-week range of $6.66 to $18.90.
- Cantor Fitzgerald maintained its 'buy' rating for ARS Pharmaceuticals with a $30 price target as of May 28, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Eric Karas, the Chief Commercial Officer at ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY), made a notable purchase of 25,000 shares on June 12, 2026. He bought these shares at an average price of $1.5 each, amounting to a total transaction value of $37,500. This transaction was not part of a pre-arranged trading plan.
Other Institutional Activity in ARS Pharmaceuticals
In other institutional activity, Rubric Capital Management LP increased its holdings by 1.8 million shares, reaching a total of 8 million shares valued at about $64.2 million. Millennium Management LLC also bolstered its position significantly, adding 2.8 million shares to end with 5.98 million shares worth approximately $48 million. Meanwhile, BlackRock, Inc. trimmed its stake by 73,063 shares, holding 5.01 million shares valued at around $40.2 million.
ARS Pharmaceuticals, Inc. Stock Up 65.7%
Shares of ARS Pharmaceuticals, trading under the ticker SPRY on NasdaqGM, were priced at $9.76 recently. The company has a market capitalization of approximately $969.2 million. It holds a forward P/E ratio of -10.19, indicating it is not currently profitable. The stock's 52-week range spans from $6.66 to $18.90, with a 50-day moving average of $8.44 and a 200-day moving average of $9.43. The company's current ratio stands at 4.94, with a quick ratio of 4.65 and a debt-to-equity ratio of 279.24.
$SPRY stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
ARS Pharmaceuticals reported revenue of $98.99 million, with a revenue growth rate of 1.85%. However, the company posted a net margin of -200.004%, reflecting ongoing financial challenges. The return on equity was -136.403%, and the next earnings report is expected on August 13, 2026.
Insider Buying and Selling at ARS Pharmaceuticals, Inc.
On June 12, 2026, Eric Karas, the Chief Commercial Officer, not only purchased 25,000 shares at $1.5 each but also sold 25,000 shares at $10. Additionally, Alexander Fitzpatrick, Chief Legal Officer, sold 3,355 shares at $10 each. Earlier in the year, on January 2, 2026, both Karas and Fitzpatrick bought 240,000 shares without any disclosed purchase price.
Analysts Set New Price Targets
On May 28, 2026, Cantor Fitzgerald maintained its 'buy' rating for ARS Pharmaceuticals, setting a price target of $30. The consensus among analysts is a 'strong buy,' with an average target price of $28.80 based on five analyst opinions.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California. Founded in 2015, the company focuses on developing treatments for severe allergic reactions, including a needle-free intranasal delivery of epinephrine called neffy. The company operates in the biotechnology sector and is led by CEO Richard E. Lowenthal.
Bottom Line
Eric Karas's recent share purchase highlights his confidence in ARS Pharmaceuticals, a company working on innovative allergy treatments. The stock's current trading range and analyst ratings suggest investor interest, despite its lack of profitability. Remember, insider transactions like these are reported after the fact and may not reflect current holdings.
Get ARS Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SPRY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.